Friday, July 10, 2026

Drug profile · INN

human coagulation factor viii / human von willebrand factor

human coagulation factor viii / human von willebrand factor (VONCENTO) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Blood and blood forming organs (B02) B02BD06
Patents linked 11
Pipeline programs 11
News articles 0
Drug details — human coagulation factor viii / human von willebrand factor
Class
Blood and blood forming organs (B02)
Route
Patents
11
Programs
11
Data quality
0.83

Quick answer

human coagulation factor viii / human von willebrand factor (VONCENTO) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN human coagulation factor viii / human von willebrand factor
Brand VONCENTO
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD06

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. Coagulation Factor VIIa (Recombinant) Phase 3 · HRA Pharma · Hemophilia
  2. LTE15174 Phase 3 · Genzyme Europe · Hemophilia A or Hemophilia B
  3. WP45338 Phase 3 · HOFFMANN-LA ROCHE · Type 3 Von Willebrand Disease
  4. Coagulation Factor IX variant Phase 2 · CATALYST PHARMACEUTICALS · Hemophilia B
  5. Coagulation Factor VIIa variant Phase 2 · CATALYST PHARMACEUTICALS · Hemophilia A With Inhibitor
  6. Coagulation Factor VIIa variant Phase 2 · CATALYST PHARMACEUTICALS · Factor VII Deficiency
  7. TTP889 Phase 2 · vTv Therapeutics · Coagulation
  8. Will receive HH-009 injection 20 mg/kg, Q3W Phase 2 · Huahui Health · Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Related patents

  1. US 12391658

    Sulfoxide and sulfone glucokinase activators and methods of use thereof

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11970457

    Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11883383

    Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11524942

    Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11096946

    Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10456406

    Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 9968613

    Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 9707239

    Compounds that modulate oxidative stress

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 9487493

    Use of a PPAR-delta agonist for treating muscle atrophy

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 9447468

    Compounds that modulate oxidative stress

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 9198901

    Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is human coagulation factor viii / human von willebrand factor?

human coagulation factor viii / human von willebrand factor (VONCENTO) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for human coagulation factor viii / human von willebrand factor?

VONCENTO is a marketed brand name for human coagulation factor viii / human von willebrand factor. Check FDA Drugs@FDA for the current US label holder and prescribing information.